MEGAN WANG to Treatment Outcome
This is a "connection" page, showing publications MEGAN WANG has written about Treatment Outcome.
Connection Strength
0.037
-
Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE. Blood. 2024 Dec 26; 144(26):2706-2717.
Score: 0.019
-
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment. Future Oncol. 2024 Apr; 20(12):717-726.
Score: 0.018